Ina Park Rhee
Genentech · 53 works · 6,281 citations · h-index 18
Top works
- DNMT1 and DNMT3b cooperate to silence genes in human cancer cells
- Interaction of Tyrosine-Based Sorting Signals with Clathrin-Associated Proteins
- CpG methylation is maintained in human cancer cells lacking DNMT1
- Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene
- Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
- Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
- Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC).
- RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer
- De novo CpG Island Methylation in Human Cancer Cells
- Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
- Mutational Analysis of the Fusion Peptide of the Human Immunodeficiency Virus Type 1: Identification of Critical Glycine Residues
- A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors.
- Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
- Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy
- Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer
- First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
- Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer
- Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer
- Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors
- Clinical translation of ferumoxytol‐based vessel size imaging (VSI): Feasibility in a phase I oncology clinical trial population